Since PGF expression increases locally in the tumor milieu upon PARPi treatment (Fig. 2), it is possible that a minor subpopulation of Brca1- and Bard1-deficient tumor cells that express the PGF receptor FLT1 prior to PARPi treatment becomes enriched in the PARPi-resistant tumors. This evidence concerns the gene BARD1 and neoplasm.